- Drugs
- Monday, 23 Mar 2020
AIkido Pharma Adds Artificial Intelligence Leader to Advisory Board
Mr. Typaldos is a pioneer software and technology entrepreneur, and a private equity investor through a Typaldos Family Office. Currently, he is founder and Executive Chairman of technology companies in the general AI and specialized AI-driven FinTech and MarTech space, CLOUD computing and IT Infrastructure Management, and enterprise software, including:
- A publicly traded AI and CLOUD software holding company, www.bciienterprises.com;
- A general AI technology company, www.cogia.de;
- Three FinTech and MarTech AI companies: www.coinanalyst.tech, www.stockanalyst.tech, and www.sometoo.de; and
- A Linux enterprise software company for email and communications, www.scalix.com, through strategic financing and technology alliance from Microsoft.
Also, together with leading scientists in Drug Development at Tufts University and the Fudan University in Shanghai and the Shanghai Center for Drug Discovery and Development, he is on the Board of Directors of Quantitative Cell Diagnostix, www.qcd-x.com, an advanced medical device and research company utilizing 3D optical tomography and data analytics for the early identification of circulating tumor cells (CTC).
In the past, Mr. Typaldos was founder, founding investor, Board Member, and Chief Executive of a number of software, technology, consulting services, and internet companies, including:
- Xandros, Inc, a Linux operating system software company that had a strategic alliance with Microsoft and provided the Linux (pre-Android) operating system to power-up the netbook mobile device market (ie, the Asus EeePC) that helped usher-in tablets;
- Enikia/Arkados, now known as IOTA Communications, a pioneer fabless semiconductor company that developed technology sold to the fifth-largest semiconductor company in the world (ST Micro) and that became part of the IEEE standard for powerline networking (using a home's electrical wiring); and,
- Computron Technologies, which was one of the very first enterprise software companies and had one of the biggest (half billion dollar) enterprise software IPO's in 1995.
Anthony Hayes, CEO of AIkido, noted "Mr. Typaldos is an industry leader in Artificial Intelligence and Machine Learning. His participation on our advisory board will help the Company expand its Artificial Intelligence (AI) and Machine Learning (ML) presence in the drug development field. We are honored he has agreed to lend his expertise and we are excited to work with him."
Accepting the appointment, Andreas Typaldos said, "I'm very excited to work with Anthony on his large vision for AIkido, and its compelling opportunity for drug development by taking advantage of breakthrough technologies like AI, ML, and Big Data."
Related Industry Updates
Pharmaceutical Waste Disposal and Management Market is expected to reach US$ 6,377.95 million by 2030
Jan 10, 2024
Clinic Casting and Splinting Products Market is expected to reach US$ 2,085.57 million by 2030
Aug 02, 2023
Antifungal Drugs Market is expected to reach US$ 13,997.4 Million in 2028
Jan 16, 2023
Emerging nations represent an excellent opportunity for the pharmaceutical industry to develop anti-fungal drugs
Sep 24, 2019
Kinderfarms Announces Kinderlyte® Advanced, Provides Natural Rehydration for Adults and Children
Mar 02, 2020
Mediterranean Fish Vaccine Market is expected to reach US$ 2,09,030.80 million by 2030
Aug 10, 2023
Pivot Pharma Launches Canadian Cannabis and Nutraceutical Manufacturing Facility
Nov 25, 2019